



INTERNALLY FUNDED

EXTERNALLY FUNDED

PRODUCT	INDICATION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	PARTNER/COLLABORATOR/FUNDER
---------	------------	--------------	---------	---------	---------	-----------------------------








**HPV-TARGETED**

VGX-3100	Cervical Dysplasia (HSIL)	Internally Funded				
	Anal Dysplasia (HSIL) (HIV-)	Internally Funded				
	Vulvar Dysplasia (HSIL)	Internally Funded				
	Cervical Dysplasia (HSIL) - China	Externally Funded				
	Anal Dysplasia (HSIL) (HIV+)	Externally Funded				
INO-3107	Recurrent Respiratory Papillomatosis (RRP)	Internally Funded				




**IMMUNO-ONCOLOGY**

INO-5401	Glioblastoma (GBM)	Internally Funded				<b>REGENERON</b>
----------	--------------------	-------------------	--	--	--	------------------

**INFECTIOUS DISEASES**

INO-4800	COVID-19 (Solidarity)	Externally Funded				
INO-4201	Ebola (Booster)	Externally Funded				  
	HIV	Externally Funded				  

**dMAb™**

	COVID-19	Externally Funded				  
INO-A002	Zika	Externally Funded				